6:30 PM – 7:00 PM Registration and Dinner
7:00 PM – 7:05 PM Welcome and Introduction
7:00 PM – 7:05 PM Immune Checkpoint Inhibitors in Cancer Treatment: Overview
7:05 PM – 8:35 PM How to Use Current Predictors of Response to Immune Checkpoint Inhibitors
- TMB and MSI/MMR to select optimal therapy
- PD-L1 testing and impact on treatment choice
- Best practices for sample collection and biomarker testing
8:35 PM – 8:50 PM Future Directions in Cancer Immunotherapy Biomarker Development
8:50 PM – 9:00 PM Final Thoughts, and Audience Question and Answer Session
Advanced Registration for this session is now closed. Please proceed to
Regency V at the Hyatt Regency Atlanta for onsite registration.
Scott Kopetz, MD, PhD, FACP
Department of Gastrointestinal Medical Oncology
University of Texas M. D. Anderson Cancer Center
Jason N. Rosenbaum, MD
Assistant Professor of Clinical Pathology and Laboratory Medicine
University of Pennsylvania Perelman School of Medicine
David R. Spigel, MD
Chief Scientific Officer
Director, Lung Cancer Research Program
Sarah Cannon Research Institute
The goal of this activity is to improve the knowledge of and competence in applying the latest data, on-going clinical trials, and new biomarkers for treatment with cancer immunotherapy
This program is intended for physicians and oncologists and other healthcare and laboratory professionals who care for patients with cancer who are candidates for cancer immunotherapy.
- Outline the biologic basis for the development of immune checkpoint inhibitors to combat cancer
- Summarize ongoing research regarding the utility of biomarkers, tumor mutational burden, T-cell functional state, LAG-3, composite biomarkers, or other host factors predictive of response to immune checkpoint inhibitors
- Compare and contrast the different methodologies and assays for identifying biomarkers of response to immune checkpoint inhibitors in different tumor types and treatment settings
- Implement best practices for biomarker testing/interpretation of results to guide treatment selection in different tumor types and treatment settings
- Improve interdisciplinary collaboration/communication to aid the optimal of selection of patients for cancer immunotherapy
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation of Credit
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.